A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients
- Conditions
- Herpes SimplexHIV Infections
- Registration Number
- NCT00002084
- Lead Sponsor
- Glaxo Wellcome
- Brief Summary
To determine the safety and efficacy of oral valacyclovir hydrochloride ( 256U87 ) compared to acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients with CD4 counts = or \> 100 cells/mm3.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (46)
Univ of South Alabama
πΊπΈMobile, Alabama, United States
Univ of Arizona / Health Science Ctr
πΊπΈTucson, Arizona, United States
Combat Group
πΊπΈLos Angeles, California, United States
Los Angeles County - USC Med Ctr
πΊπΈLos Angeles, California, United States
Infectious Disease Med Group / Adult Immunology Clinic
πΊπΈOakland, California, United States
UCI Med Ctr
πΊπΈOrange, California, United States
UCSD Med Ctr
πΊπΈSan Diego, California, United States
San Diego Naval Hosp
πΊπΈSan Diego, California, United States
ViRx Inc
πΊπΈSan Francisco, California, United States
UCSF - San Francisco Gen Hosp
πΊπΈSan Francisco, California, United States
Scroll for more (36 remaining)Univ of South AlabamaπΊπΈMobile, Alabama, United States